Table 2.
Analyses of prognostic factors for survival.
| Factor | Overall survival | Progression-free survival | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Sex | ||||||||
| Female/Male | 1.459 (0.713-2.984) | 0.301 | 0.951 (0.450-2.009) | 0.895 | ||||
| Age (years) | ||||||||
| <60/≥60 | 1.118 (0.631-1.981) | 0.703 | 0.971 (0.581-1.626) | 0.912 | ||||
| ECOG PS | ||||||||
| 1/0 | 1.587 (0.897-2.809) | 0.113 | 1.271 (0.748-2.162) | 0.376 | ||||
| HBsAg | ||||||||
| Positive/Negative | 1.632 (0.699-3.810) | 0.257 | 1.045 (0.533-2.046) | 0.899 | ||||
| Child-Pugh class | ||||||||
| B/A | 1.698 (0.800-3.606) | 0.168 | 1.243 (0.631-2.448) | 0.530 | ||||
| AFP level (μg/L) | ||||||||
| ≥400/<400 | 1.317 (0.779-2.225) | 0.304 | 1.146 (0.718-1.828) | 0.568 | ||||
| PIVKA-II (mAU/mL) | ||||||||
| ≥400/<400 | 1.275 (0.714-2.274) | 0.411 | 1.387 (0.829-2.319) | 0.212 | ||||
| Recurrent tumor | ||||||||
| No/Yes | 1.480 (0.723-3.030) | 0.283 | 1.013 (0.561-1.829) | 0.965 | ||||
| Number of tumors | ||||||||
| >3/≤3 | 1.528 (0.893-2.615) | 0.122 | 1.177 (0.733-1.888) | 0.500 | ||||
| Tumor distribution | ||||||||
| Bilobar/Unilobar | 1.144 (0.647-2.022) | 0.643 | 1.033 (0.623-1.711) | 0.900 | ||||
| Largest tumor size (cm) | ||||||||
| ≥10/<10 | 1.531 (0.857-2.733) | 0.150 | 1.388 (0.836-2.304) | 0.205 | ||||
| Main portal vein invasion | ||||||||
| Yes/No | 1.638 (0.970-2.767) | 0.065 | 1.867 (1.089-3.200) | 0.023 | 1.025 (0.635-1.653) | 0.920 | ||
| Hepatic vein invasion | ||||||||
| Yes/No | 1.263 (0.721-2.211) | 0.414 | 1.315 (0.783-2.206) | 0.300 | ||||
| Extrahepatic metastasis | ||||||||
| Yes/No | 1.710 (1.013-2.888) | 0.045 | 2.041 (1.183-3.520) | 0.010 | 2.125 (1.313-3.438) | 0.002 | 2.337 (1.430-3.820) | 0.001 |
| Treatment option | ||||||||
| TACE-L/TACE-L-P | 1.987 (1.172-3.367) | 0.011 | 2.065 (1.208-3.533) | 0.008 | 2.100 (1.288-3.425) | 0.003 | 2.312 (1.404-3.808) | 0.001 |
| TACE technique | ||||||||
| cTACE/DEB-TACE | 1.188 (0.706-2.001) | 0.517 | 1.311 (0.817-2.103) | 0.262 | ||||
Analyses were performed using Cox proportional hazard regression model. HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HBsAg, hepatitis B surface antigen; AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist-II; TACE-L, transarterial chemoembolization combined with lenvatinib; TACE-L-P, transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor; TACE, transarterial chemoembolization; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization.